Isosorbide 5-Mononitrate
Isosorbide 5-Mononitrate Information

About Isosorbide 5-Mononitrate

Isosorbide 5-MononIitrate is a potent coronary vasodialator used for prophylaxis of angina. An active metabolite of Isosorbide dinitrate, Isosorbide 5-Mononitrate is not metabolized further and may thus have a more predictable effect. Adverse effects are similar toGlyceral Trinitrate.

Indications

Isosorbide 5-Mononitrate is primarily indicated in conditions like Congestive heart failure, Prevention and treatment of scurvy, Prophylaxis of angina.

Contraindication

Isosorbide 5-Mononitrate is contraindicated in conditions like Glucoma,Cardiogenic shock,Obstructive cardiomyopathy,Constrictive pericarditis,Low cardiac filling pressure,Hypersensitivity,Raised intracranial pressure,Aortic stenosis,Mitral stenosis,Acute circulatory failure,Severe hypotension,Pericardiac tamponade,Arterial hypoxemia,Orthostatic disturbance of circulatory regulation.

Side Effects

The severe or irreversible adverse effects of Isosorbide 5-Mononitrate, which give rise to further complications include Hypotension, Hypotension, Orthostatic hypotension, Collapse, Decreased cardiac output, Paradoxical bradycardia.The signs and symptoms that are produced after the acute overdosage of Isosorbide 5-Mononitrate include Hypotension, Tachycardia, Confusion, Palpitations, Headache, Syncope, Neurologic deficit, Increased intracranial pressure, Flushed skin.The symptomatic adverse reactions produced by Isosorbide 5-Mononitrate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Dizziness, Vertigo, Headache, Nausea, Vomiting, Myalgia, Palpitation, Hypotension, Urinary incontinence, Allergic skin reactions, Fecal incontinence, Orthostatic hypotension, Apprehension, dizziness, Weakness.

Warnings

Excessive use of isosorbide 5-mononitrate may cause headache, so reduce the dose and use analgesics (painkiller). In terminating treatment of angina, gradually reduced the dose in order to avoid withdrawal reactions. Extended-release isosorbide 5-mononitrate should be avoided in the patient with the GI disease such as the hypermotility or malabsorption syndrome, this dosage form may not be dissolved and may be excreted intact in these conditions. In making the decision to administer the drug during pregnancy, the potential risk to the fetus must be weighed against the potential benefits to the mother.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.